Netherlands· NL-d8e81bd6c2ff
LYNOZYFIC 200 mg concentraat voor oplossing voor infusie
A medicinal product containing linvoseltamab, registered in Netherlands by Regeneron Ireland Designated Activity Company.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- LINVOSELTAMAB
- Manufacturer
- Regeneron Ireland Designated Activity Company
- Country
- Netherlands (NL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/25/1917
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linvoseltamab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLYNOZYFICRegeneron Pharmaceuticals, Inc.
- CzechiaLYNOZYFICRegeneron Ireland Designated Activity Company, Dublin
- SpainLYNOZYFIC 200 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRegeneron Ireland Designated Activity Company
- FinlandLYNOZYFICRegeneron Ireland Designated Activity Company (DAC)
- IrelandLYNOZYFIC 200 mg concentrate for solution for infusionRegeneron Ireland Designated Activity Company
- IcelandLynozyficRegeneron Ireland Designated Activity Company
- BelgiumLynozyfic 200 mgRegeneron Ireland Designated Activity Company (DAC)
- PolandLynozyficRegeneron Ireland DAC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lynozyfic
- Liechtenstein · Lynozyfic
- Norway · Lynozyfic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/96dc1780-171e-4769-9bbe-be34389cfb13 GET /v1/drugs/96dc1780-171e-4769-9bbe-be34389cfb13?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/lynozyfic-epar-product-information_nl.pdf",
"strength": null,
"atc_label": null,
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp132892",
"excipients": [
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"POLYSORBAAT 80 (E 433)",
"SACCHAROSE",
"WATER VOOR INJECTIE"
],
"substances": [
"LINVOSELTAMAB"
],
"leaflet_url": null,
"authorised_at": "2025/04/23",
"procedure_number": "EMEA/H/C/006370",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/25/1917",
"additional_monitoring": "Y"
}See everything about linvoseltamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.